Lacutamab + Gemcitabine + Oxaliplatine
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T Cell Lymphoma
Conditions
Peripheral T Cell Lymphoma, Relapse/Recurrence
Trial Timeline
Oct 5, 2021 → Jan 30, 2028
NCT ID
NCT04984837About Lacutamab + Gemcitabine + Oxaliplatine
Lacutamab + Gemcitabine + Oxaliplatine is a phase 2 stage product being developed by Innate Pharma for Peripheral T Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04984837. Target conditions include Peripheral T Cell Lymphoma, Relapse/Recurrence.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04984837 | Phase 2 | Recruiting |
Competing Products
20 competing products in Peripheral T Cell Lymphoma